Health Care & Life Sciences » Biotechnology | Aimmune Therapeutics Inc.

Aimmune Therapeutics Inc. | Ownership

Companies that own Aimmune Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
T. Rowe Price Associates, Inc.
4,653,941
7.96%
161,864
0.02%
06/30/2018
The Vanguard Group, Inc.
3,358,421
5.74%
118,443
0%
06/30/2018
BlackRock Fund Advisors
3,274,925
5.6%
529,879
0.01%
06/30/2018
SSgA Funds Management, Inc.
2,370,299
4.05%
521,617
0.01%
06/30/2018
Fidelity Management & Research Co.
2,243,971
3.84%
-371,200
0.01%
06/30/2018
Wellington Management Co. LLP
1,848,145
3.16%
-213,047
0.01%
06/30/2018
Point72 Asset Management LP
1,688,783
2.89%
608,883
0.23%
06/30/2018
Eventide Asset Management LLC
1,620,000
2.77%
55,017
1.72%
06/30/2018
AllianceBernstein LP
1,523,871
2.61%
191,930
0.02%
06/30/2018
Palo Alto Investors LP
1,381,759
2.36%
25,245
1.48%
06/30/2018

About Aimmune Therapeutics

View Profile
Address
8000 Marina Boulevard
Brisbane California 94005
United States
Employees -
Website http://www.aimmune.com
Updated 07/08/2019
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.